The coronavirus pandemic can be titled as one of the most unparalleled, tough global challenges that the world has had to face. With over 11 million cases reported globally, and a death toll of more than 5 lakhs, the WHO has said that the pandemic is far from being over, and the worst is yet to come.
During testing times like these, the entire world has their eyes on science, medical experts, and researchers, who are tirelessly working towards finding an effective vaccine against the novel coronavirus, which may be the only ray of hope currently to prevent the infection, and slow down the spread of the pandemic. With more than a hundred vaccine candidates under development around the world, a few of them have reached the stages of final trials, and seem promising. Here is a review of the many vaccine candidates that are under trials or development.
Oxford’s COVID-19 vaccine leading the race
Oxford University’s candidate for COVID-19 vaccine seems to be leading the race, globally. The vaccine is not only in its final phase of trials that are being conducted in Brazil, but it is also already under production as it was licensed to British Pharma Giant, AstraZeneca. AstraZeneca has already partnered with the Serum Institute of India for the production of 500 million doses in the country. A production deal with Brazil is also underway. The project leader has also said that the vaccine has shown very good results in clinical trials and is currently on the right track.
PharmaJet & Moderna all set to conduct Phase 3 trials in July
US-based PharmaJet® has said that it still expects to begin a phase-3 clinical trial of its Covid-19 vaccine candidate in July after a report said that the late-stage trial of the vaccine involving 30,000 participants got delayed due to changes in the study plan. The initial trials were scheduled to begin on the 9th of July. The maker of innovative, needle-free injection technology, has announced that its Needle-free Injection System technology will be used to deliver a messenger RNA (mRNA) vaccine against SARS-CoV-2. The vaccine is being developed by Abnova Corporation, the world’s largest antibody manufacturer, based in Taiwan.
Abnova has established a comprehensive portfolio of fully integrated solutions to address the needs for responding to SARS-CoV-2, including a novel adjuvant that can further increase the effectiveness of their mRNA candidate.
“We have taken a major next step toward mRNA vaccine development against COVID-19 based on the specific gene sequences generating successful antibody response from our DNAx™ Immune platform,” said Dr. Wilber Huang, President, and CEO, Abnova. “We would like to compliment the mRNA immunization with a needle-free platform to further augment the protective antibody response against COVID-19 with an
Sinovac’s Coronavac raises hopes
Sinovac Biotech Ltd, a leading biopharmaceutical company in China, entered stage 2 trials of its COVID-19 antibody vaccine named CoronaVac. The trials for the vaccine are being conducted with more than 1,000 participants. Last month, the company said it is 99 percent certain that its experimental coronavirus vaccine ‘CoronaVac’ will work effectively against the SARS-CoV-2 virus that causes COVID-19.
BioNTech and Pfizer’s COVID-19 vaccine joins the race with positive results
A COVID-19 vaccine developed by German biotech firm BioNTech and US pharmaceutical giant Pfizer has shown potential and was found to be well tolerated in early-stage human trials, the companies recently said in a statement. While the vaccine is still in the initial stages of the trial, the companies are ready to conduct a large trial involving up to 30,000 participants in July.
J&J to join the race within a fortnight
Last week, it was reported that J&J will begin the first phase of clinical trials for its COVID-19 vaccine in a fortnight. The US-based pharma giant, which has already advanced its schedule of starting human trials of its candidate vaccine to the second half of July from September, is working on the twin fronts of expanding existing manufacturing capacity and establishing new units, Chief Scientific Officer Paul Stoffels told PTI.
COVID-19 vaccines closer to home – India buckles up in a race against Coronavirus
Bharat Biotech takes the first step towards a home-grown COVID vaccine
Last week, Bharat Biotech became India’s first pharma firm to receive DCGI nod for clinical trials. The vaccine candidate developed by Bharat Biotech in collaboration with the Indian Council for Medical Research and National Institute of Virology has been named COVAXIN. To get faster results, the ICMR has asked 12 medical colleges around the country to expedite the trials. The ICMR hopes to launch the results of the trials on 15th August 2020, which is also celebrated as Independence Day in the country.
Zydus Cladia also receives DCGI nod for trials
Days after Bharat Biotech became the first to receive DCGI nod for clinical trials, another home-grown vaccine from Zydus Cladia has received the drug controller’s approval for clinical trials. The vaccine candidate was reportedly given the go-ahead by the DCGI to conduct phase I and phase II human clinical trials after animal studies were found satisfactory.
Powder-based, Needle-free Injection System Market 2020: Latest Analysis
Chicago, United States:-ThePowder-based, Needle-free Injection System marketreport5 Years Forecast [2020-2025]focuses on the COVID19 Outbreak Impact analysis of key points influencing the growth of the market. The research report on the Powder-based, Needle-free Injection System Market is a deep analysis of the market. This is the latest report, covering the current COVID-19 impact on the Powder-based, Needle-free Injection System market. The pandemic of COVID-19 has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact are covered in the report. Experts have studied the historical data and compared it with the changing market situations. The report covers all the necessary information required by new entrants as well as the existing players to gain deeper insight.
Furthermore, the statistical survey in the report focuses on product specifications, costs, production capacities, marketing channels, and market players. Upstream raw materials, downstream demand analysis, and a list of end-user industries have been studied systematically, along with the suppliers in this market. The product flow and distribution channel have also been presented in the research report.
Also Read : News Highlights From July 2020